Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 273-289 , April 2009

Clinical management of adrenocortical carcinoma

  • Martin Fassnacht, MD (Max Eder Senior Research Fellow, Consultant Endocrinologist)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49-0931-201-36507; Fax: +49-0931-201-36766.
    • ,
  • Bruno Allolio, MD (Professor of Medicine, Consultant Endocrinologist)

References 

  1. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (‘incidentaloma’). Annals of Internal Medicine. 2003;138:424–429
  2. Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine Reviews. 2004;25:309–340
  3. Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. Journal of Endocrinological Investigation. 2006;29:298–302
  4. Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR American Journal of Roentgenology. 2008;190:1163–1168
  5. National-Cancer-Institute Third National Cancer Survey: Incidenca Data. DHEW Publ. No. (NIH) 75-787. NCI monograph 1975;41
  6. Wajchenberg B, Albergaria PM, Medonca B, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer. 2000;88:711–736
  7. Dackiw AP, Lee JE, Gagel RF, et al. Adrenal cortical carcinoma. World Journal of Surgery. 2001;25:914–926
  8. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2027–2037
  9. Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?. World Journal of Surgery. 2006;30:872–878
  10. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. The New England Journal of Medicine. 1990;322:1195–1201
  11. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer. 1993;72:3145–3155
  12. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World Journal of Surgery. 2001;25:891–897
  13. Koschker AK, Fassnacht M, Hahner S, et al. Adrenocortical carcinoma: improving patient care by establishing new structures. Experimental and Clinical Endocrinology & Diabetes. 2006;114:45–51
  14. Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2650–2655
  15. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer. 2007;14:13–28
  16. Seccia TM, Fassina A, Nussdorfer GG, et al. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer. 2005;12:149–159
  17. Arlt W, Hahner S, Libe R, et al. Steroid profiling in the diagnosis and monitoring of adrenocortical cancer - results of the EURINE ACC Study of the European Network For The Study Of Adrenal Tumors (ENS@T). Abstracts of the 90th annual meeting of the Endocrine Society, San Francisco; 2008. p. OR40–2.
  18. Barzon L, Boscaro M. Diagnosis and management of adrenal incidentalomas. The Journal of Urology. 2000;163:398–407
  19. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. The Journal of Clinical Endocrinology and Metabolism. 2000;85:637–644
  20. Fassnacht M, Kenn W, Allolio B. Adrenal tumors: how to establish malignancy?. Journal of Endocrinological Investigation. 2004;27:387–399
  21. Ilias I, Sahdev A, Reznek RH, et al. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007;14:587–599
  22. Heinz-Peer G, Memarsadeghi M, Niederle B. Imaging of adrenal masses. Current Opinion in Urology. 2007;17:32–38
  23. Boland GW, Lee MJ, Gazelle GS, et al. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR American Journal of Roentgenology. 1998;171:201–204
  24. Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. The Journal of Clinical Endocrinology and Metabolism. 2005;90:871–877
  25. Pena CS, Boland GW, Hahn PF, et al. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology. 2000;217:798–802
  26. Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology. 2002;222:629–633
  27. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005;234:479–485
  28. Park BK, Kim CK, Kim B, et al. Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses. Radiology. 2007;243:760–765
  29. Korobkin M, Giordano TJ, Brodeur FJ, et al. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology. 1996;200:743–747
  30. Honigschnabl S, Gallo S, Niederle B, et al. How accurate is MR imaging in characterisation of adrenal masses: update of a long-term study. European Journal of Radiology. 2002;41:113–122
  31. Al-Hawary MM, Francis IR, Korobkin M. Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. Best Practice & Research. Clinical Endocrinology & Metabolism. 2005;19:277–292
  32. Faria JF, Goldman SM, Szejnfeld J, et al. Adrenal masses: characterization with in vivo proton MR spectroscopy–initial experience. Radiology. 2007;245:788–797
  33. Gross MD, Shapiro B, Francis IR, et al. Scintigraphy of incidentally discovered bilateral adrenal masses. European Journal of Nuclear Medicine. 1995;22:315–321
  34. Han SJ, Kim TS, Jeon SW, et al. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning. International Journal of Clinical Practice. 2007;61:802–809
  35. Caoili EM, Korobkin M, Brown RK, et al. Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. Academic Radiology. 2007;14:468–475
  36. Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. Journal of Nuclear Medicine. 2006;47:32–37
  37. Khan TS, Sundin A, Juhlin C, et al. 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging. 2003;30:403–410
  38. Hennings J, Lindhe O, Bergstrom M, et al. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. The Journal of Clinical Endocrinology and Metabolism. 2006;91:1410–1414
  39. Hahner S, Stuermer A, Kreissl M, et al. [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. The Journal of Clinical Endocrinology and Metabolism. 2008;93:2358–2365
  40. Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2665–2671
  41. Leboulleux S, Dromain C, Bonniaud G, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. The Journal of Clinical Endocrinology and Metabolism. 2006;91:920–925
  42. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12:667–680
  43. Volante M, Buttigliero C, Greco E, et al. Pathological and molecular features of adrenocortical carcinoma: an update. Journal of Clinical Pathology. 2008;61:787–793
  44. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. American Journal of Surgical Pathology. 1989;13:202–206
  45. Hough AJ, Hollifield JW, Page DL, et al. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data. American Journal of Clinical Pathology. 1979;72:390–399
  46. van Slooten H, Schaberg A, Smeenk D, et al. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer. 1985;55:766–773
  47. Goldblum JR, Shannon R, Kaldjian EP, et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Modern Pathology. 1993;6:663–668
  48. Vargas MP, Vargas HI, Kleiner DE, et al. Adrenocortical neoplasms: role of prognostic markers MIB-1, P53, and RB. American Journal of Surgical Pathology. 1997;21:556–562
  49. Terzolo M, Boccuzzi A, Bovio S, et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology. 2001;57:176–182
  50. Wachenfeld C, Beuschlein F, Zwermann O, et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful?. European Journal of Endocrinology. 2001;145:335–341
  51. Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocrine Journal. 2008;55:49–55
  52. Saeger W. Histopathological classification of adrenal tumours. European Journal of Clinical Investigation. 2000;30:58–62
  53. Saeger W, Fassnacht M, Chita R, et al. High diagnostic accuracy of adrenal core biopsy: results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients. Human Pathology. 2003;34:180–186
  54. Sasano H, Suzuki T, Moriya T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocrine Pathology. 2006;17:345–354
  55. Tissier F, Louvel A, Grabar S, et al. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. European Journal of Endocrinology. 2004;150:809–817
  56. Libe R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. European Journal of Endocrinology. 2005;153:477–487
  57. DeLellis RA, Lloyd RV, Heitz PU, et al. World Health Organization classification of tumours. Pathology and Genetics of Tumours of Endocrine Organs. 2004;p. 136
  58. Macfarlane DA. Cancer of the adrenal cortex: the natural history, prognosis and treatment in a study of fifty-five cases. Annals of the Royal College of Surgeons of England. 1958;23:155–186
  59. Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. The Journal of Urology. 1978;120:660–665
  60. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 UICC staging classification for adrenocortical carcinoma - proposal for a revised TNM classification. Cancer 2009 Jan 15;115(2): 243–250.
  61. Hedican SP, Marshall FF. Adrenocortical carcinoma with intracaval extension. The Journal of Urology. 1997;158:2056–2061
  62. Gonzalez RJ, Shapiro S, Sarlis N, et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery. 2005;138:1078–1085[discussion: 1085–6]
  63. Kebebew E, Siperstein AE, Clark OH, et al. Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms. Archives of Surgery. 2002;137:948–951[discussion: 952–3]
  64. Schlamp A, Hallfeldt K, Mueller-Lisse U, et al. Recurrent adrenocortical carcinoma after laparoscopic resection. Nature Clinical Practice, Endocrinology & Metabolism. 2007;3:191–195quiz 1 p following 195
  65. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery. 1992;112:963–970[discussion: 970–1]
  66. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. Journal of Clinical Oncology. 2002;20:941–950
  67. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment in patients with adrenocortical carcinoma. The New England Journal of Medicine. 2007;356:372–380
  68. Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. The Journal of Clinical Endocrinology and Metabolism. 2006;91:4501–4504
  69. Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Annals of Oncology. 2000;11:1281–1287
  70. Wood BJ, Abraham J, Hvizda JL, et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer. 2003;97:554–560
  71. Rhim H, Dodd GD, Chintapalli KN, et al. Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. Radiographics. 2004;24:41–52
  72. Brown DB. Concepts, considerations, and concerns on the cutting edge of radiofrequency ablation. Journal of Vascular and Interventional Radiology. 2005;16:597–613
  73. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12:657–666
  74. Kirschner LS. Emerging treatment strategies for adrenocortical carcinoma: a new hope. The Journal of Clinical Endocrinology and Metabolism. 2006;91:14–21
  75. Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. The Journal of Clinical Endocrinology and Metabolism. 2008;93:2057–2062
  76. Samnotra V, Vassilopoulou-Sellin R, Fojo AT. A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 2007;[abstract no 15527]
  77. Chacon R, Tossen G, Loria FS, et al. CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. Journal of Clinical Oncology. 2005;23:1579–1580
  78. Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. American Journal of Pathology. 2003;162:521–531
  79. de Fraipont F, El Atifi M, Cherradi N, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. The Journal of Clinical Endocrinology and Metabolism. 2005;90:1819–1829
  80. Almeida MQ, Fragoso MC, Lotfi CF, et al. Expression of IGF-II and its receptor in pediatric and adult adrenocortical tumors. The Journal of Clinical Endocrinology and Metabolism 2008 Sep;93(9): 3524–3531.
  81. Miller JW, Crapo L. The medical treatment of Cushing's syndrome. Endocrine Reviews. 1993;14:443–458
  82. Fassnacht M, Hahner S, Beuschlein F, et al. New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line. European Journal of Clinical Investigation. 2000;30(Suppl. 3):76–82
  83. Contreras P, Rojas A, Biagini L, et al. Regression of metastatic adrenal carcinoma during palliative ketoconazole treatment. Lancet. 1985;2:151–152
  84. Johanssen S & Allolio B. Mifepristone (RU 486) in Cushing's syndrome. European Journal of Endocrinology 2007; 157: 561–569; Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. 2009 Mar 16. [Epub ahead of print].
  85. Schulte HM, Benker G, Reinwein D, et al. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. The Journal of Clinical Endocrinology and Metabolism. 1990;70:1426–1430
  86. Bergenstal D, Lipsett M, Moy R, et al. Regression of adrenal cancer and suppression of adrenal function in men by o,p-DDD. Transactions of American Physicians. 1959;72:341
  87. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Current Opinion in Investigational Drugs. 2005;6:386–394
  88. van Slooten H, Moolenaar AJ, van Seters AP, et al. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. European Journal of Cancer & Clinical Oncology. 1984;20:47–53
  89. Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. British Journal of Cancer. 1994;69:947–951
  90. Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001;92:1385–1392
  91. Terzolo M, Pia A, Berruti A, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. The Journal of Clinical Endocrinology and Metabolism. 2000;85:2234–2238
  92. Faggiano A, Leboulleux S, Young J, et al. Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clinical Endocrinology. 2006;64:110–113
  93. Nader N, Raverot G, Emptoz-Bonneton A, et al. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2165–2170
  94. Dickstein G, Shechner C, Arad E, et al. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?. The Journal of Clinical Endocrinology and Metabolism. 1998;83:3100–3103
  95. Venkatesh S, Hickey RC, Sellin RV, et al. Adrenal cortical carcinoma. Cancer. 1989;64:765–769
  96. Soreide JA, Brabrand K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970–1984. World Journal of Surgery. 1992;16:663–667[discussion 668]
  97. Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997;122:1212–1218
  98. Schulick RD, Brennan MF. Adrenocortical carcinoma. World Journal of Urology. 1999;17:26–34
  99. Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer. 2001;92:1113–1121
  100. Assie G, Antoni G, Tissier F, et al. Prognostic parameters of metastatic adrenocortical carcinoma. The Journal of Clinical Endocrinology and Metabolism. 2007;92:148–154

PII: S1521-690X(08)00141-3

doi: 10.1016/j.beem.2008.10.008

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 273-289 , April 2009

Article Tools

* Image Usage & Resolution